Given the location of the breaks, BRWD2 is considered a candidate tumor suppressor; through our analysis we identified 80% of GBM patients versus 50% of “normal” individuals have a CAML genotype at BRWD2. Interestingly, FGFR2 and BRWD2, both genes included in the GBM signature, are an oncogene and tumor suppressor pair located at a recombination locus in which deletion of exon 21 of FGFR2 results in the exclusion of BRWD2 (the tumor suppressor) and amplification of FGFR2; thus intronic CAMLs harbored by these genes could be biological indicators for tumorigenic activity. The gene discussed is FGFR2; the disease is glioblastoma.